Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

Pfizer: Clinical Trials & FDA Approval Profile

Pfizer (New York, NY) sponsors 377 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 143 active protocols (81 recruiting now), 161 completed protocols, and 418 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)19.4%
Median Closed Enrollment vs National (145 pts)241 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Pfizer
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)377
Active Pipeline (Recruiting Now)143 (81)
Completed vs Stopped Early161 / 73 (19.4%)
Median Closed Actual Enrollment241 participants
Physical Hospital Site Disclosure99.9% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals418 (34 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Pfizer
Hospital Research SiteLocationShared Protocols
National Taiwan University HospitalTaipei66
Hospital Universitario 12 de OctubreMadrid53
Severance Hospital, Yonsei University Health SystemSeoul, Other48

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Pfizer
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT05623020A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, LePhase IIIRECRUITING
NCT05611801A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia BPhase IIIRECRUITING
NCT06698796A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory MyopathiesPhase IIIRECRUITING
NCT06807281A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe EczemaPhase IIIRECRUITING
NCT05145127Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without InhibitorsPhase IIIRECRUITING

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.

Explore interactive annual charts and M&A subsidiary rollups in the Pfizer Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI